Annual Report - Glenmark

More documents

Recommendations

Info

Contents 2 Global. Reaserch-focused. Integrated 10 Highlights, 2004-05 11 Objectives, 2005-2006 12 Interview with the CEO 16 Business Divisional Analysis 18 Domestic Formulations 22 Active Pharmaceutical Ingredients 26 International Formulations 30 Research and Development 36 Global Management Team 37 Management's Discussion and Analysis 43 Risk Management 45 Five-year Financial Summary 47 Ratios 49 Profile of Directors 50 Director's Report 61 Report on Corporate Governance 71 Auditor's Report 74 The Financial Statements
Page 1 and 2: Glenmark Pharmaceuticals Limited An
Page 3: Consolidated Financial Highlights Y
Page 7 and 8: Objective To position the Company f
Page 9 and 10: Growing competition characterises t
Page 11 and 12: A committed research and developmen
Page 13 and 14: Success in a competitive global env
Page 15 and 16: headed for the future Objectives, 2
Page 17 and 18: The Company successfully launched i
Page 19 and 20: Glenmark Pharmaceuticals Limited ar
Page 21 and 22: Glenmark has responded to challenge
Page 23 and 24: Annual Report 2004-2005 19 A multi-
Page 25 and 26: Glenmark Pharmaceuticals Limited Ne
Page 27 and 28: developing low cost routes to manuf
Page 29 and 30: Glenmark Pharmaceuticals Limited Gr
Page 31 and 32: partnering for growth Annual Report
Page 33 and 34: Glenmark Pharmaceuticals Limited fi
Page 35 and 36: Research has been integral to Glenm
Page 37 and 38: Glenmark Pharmaceuticals Limited NC
Page 39 and 40: Glenmark Pharmaceuticals Limited Di
Page 41 and 42: Management's Discussion and Analysi
Page 43 and 44: Glenmark Pharmaceuticals Limited Fi
Page 45 and 46: Glenmark Pharmaceuticals Limited Fi
Page 47 and 48: Risk Management Strategy Risk Astra
Page 49 and 50: Four year financial summary Balance
Page 51 and 52: Financial Ratios 1.8 1.2 0.6 0.77 0
Page 53 and 54: Profiles of the Directors Mr. Graci
Page 55 and 56:
OPERATIONS: PHARMA DIVISION Domesti
Page 57 and 58:
DIRECTORS’ RESPONSIBILITY STATEME
Page 59 and 60:
B. TECHNOLOGY ABSORPTION, RESEARCH
Page 61 and 62:
ANNEXURE-B Information of employees
Page 63 and 64:
ii) Any other employee who receives
Page 65 and 66:
Name of the Director Status No. of
Page 67 and 68:
Compliance Officer: Mr. M.J. Mendon
Page 69 and 70:
d) Share Holding Pattern as at Marc
Page 71 and 72:
Information in respect of such uncl
Page 73 and 74:
ESOS’ 1999 ESOS’ 2003 Date Numb
Page 75 and 76:
Auditors’ Report To the members o
Page 77 and 78:
Name of the statute Nature of dues
Page 79 and 80:
Profit and Loss Accounts Rs. In (
Page 81 and 82:
Cash Flow Statement Rs. In (’000s
Page 83 and 84:
Schedules forming part of the Balan
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Schedules to the Profit & Loss Acco
Page 91 and 92:
Schedules forming part of the Finan
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Balance Sheet Abstract & Company’
Page 105 and 106:
Consolidated Auditors’ Report Aud
Page 107 and 108:
Consolidated Profit And Loss Accoun
Page 109 and 110:
Consolidated Cash Flow Statement Rs
Page 111 and 112:
Schedules forming part of the Conso
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Notes to the Consolidated Accounts
Page 121 and 122:
Notes to the Consolidated Accounts
Page 123 and 124:
Corporate Information Chairman [Non
show all

Annual Report - Glenmark

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?